Table 3.
Incidence of extreme (low or high) concentrations/activities of MBL and MASPs in ovarian cancer patients and controls
| Parameter | Cut-off | Frequency in groups | |||
|---|---|---|---|---|---|
| C (n = 164)a | NO (n = 62)b | BT (n = 102)c | OC (n = 107)d | ||
| MBL concentration | <100 ng/ml | 27 (16.5) | 11 (17.7) | 16 (15.7) | 20 (18.7) |
| >3,000 ng/ml | 4 (2.4) | 0 | 4 (3.9) | 15 (14)e | |
| MASP-2 concentration | <191 ng/ml | 14 (8.6) | 6 (9.7) | 8 (8) | 9 (8.5) |
| >627 ng/ml | 17 (10.5) | 6 (9.7) | 11 (11) | 14 (13.2) | |
| MBL–MASP-2 activity | <60 mU/ml | 18 (11) | 4 (6.6) | 14 (13.6) | 18 (16.8) |
| >800 mU/ml | 17 (10.4) | 7 (11.5) | 10 (9.7) | 21 (19.6)f | |
| MBL–MASP-1 activity | <50 mU/ml | 34 (21) | 8 (12.9) | 26 (26) | 29 (27.1)g |
| >605 mU/ml | 17 (10.5) | 6 (9.7) | 11 (11) | 17 (15.9) | |
Percentages are given in parentheses
C, control group, including NO, patients with no ovarian pathology and BT, patients with benign ovarian tumours; OC, patients with primary ovarian cancer
a n = 162 for MASP-2 concentration and MBL–MASP-1 activity
bn = 61 for MBL–MASP-2 activity
cn = 100 for MASP-2 concentration and MBL–MASP-1 activity; n = 103 for MBL–MASP-2 activity
dn = 106 for MASP-2 concentration
e p = 0.0004; OR 6.5 (vs C); p = 0.001; OR 21 (vs NO); p = 0.01; OR 4 (vs BT)
f p < 0.05; OR 2.1(vs C)
g p = 0.035; OR 2.5 (vs NO)